Some clinical trials have been conducted to assess the targeting of metabolic changes in the treatment of PLC (Table 3); however, combined targeting of these metabolic alterations using ICB should be specifically considered as this would significantly reinvigorate the anti-tumor immune response and thus achieve better therapeutic effects. Here, HSPG2 is linked to neoplasm.